These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 18931861

  • 1. Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa.
    Pat K, Anrys B, Verhulst D, Van Aelst F, Van Eygen K, Galdermans D, Verhoeven D, Polus M, Segers K, Derde MP, Wauters I, Vansteenkiste J.
    Support Care Cancer; 2009 Feb; 17(2):211-5. PubMed ID: 18931861
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 3. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
    Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
    Curr Med Res Opin; 2011 Feb 03; 27(2):355-63. PubMed ID: 21166611
    [Abstract] [Full Text] [Related]

  • 4. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E, AMG-DAR-2002-01 Study Group.
    Curr Med Res Opin; 2008 Oct 03; 24(10):2931-42. PubMed ID: 18775103
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A.
    Clin Transl Oncol; 2011 May 03; 13(5):341-7. PubMed ID: 21596663
    [Abstract] [Full Text] [Related]

  • 6. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I, Laplaige P, Vey N, Asselain B, Urbieta M.
    Curr Med Res Opin; 2010 Nov 03; 26(11):2653-60. PubMed ID: 20932223
    [Abstract] [Full Text] [Related]

  • 7. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.
    Curr Med Res Opin; 2012 Jul 03; 28(7):1089-99. PubMed ID: 22642866
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 03; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 9. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec 03; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 10. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
    Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Aerts JG.
    Curr Med Res Opin; 2012 Jul 03; 28(7):1079-87. PubMed ID: 22642867
    [Abstract] [Full Text] [Related]

  • 11. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.
    Med Oncol; 2012 Sep 03; 29(3):2291-9. PubMed ID: 22081263
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
    Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J, Aranesp 980291 Study Group.
    Eur J Cancer; 2003 Sep 03; 39(14):2026-34. PubMed ID: 12957457
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Sep 03; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 14. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T, Kindler M, Lange O, Vehling-Kaiser U, Kuhn A, Hellebrand E.
    Curr Med Res Opin; 2014 Sep 03; 30(9):1813-20. PubMed ID: 24849527
    [Abstract] [Full Text] [Related]

  • 15. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May 03; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
    Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L.
    Br J Haematol; 2008 Jul 03; 142(3):379-93. PubMed ID: 18540943
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G, Doménech M, López P, Pedro C, Villadiego K, Constenla M, Sánchez-Rovira P, Gasquet JA, Rodríguez CA, AVANT study group.
    Tumori; 2014 Jul 03; 100(2):225-31. PubMed ID: 24852870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.